Biotech
Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
Read
Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST
Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma
Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.
Read
Commented by Juliane Zielonka on October 3rd, 2024 | 14:00 CEST
Vidac Pharma, BioNTech, Gerresheimer optimize the value chain - From research to patient
Medical innovation and rapid therapy development are gaining momentum thanks to the use of AI. In this context, companies in the pharmaceutical and biotech industry are relying on groundbreaking technologies and strategies to optimize the value chain from research to patient. Vidac Pharma is researching an innovative approach to fighting cancer by supporting the body's own immune defenses. The Company has now received a patent in the US, granting exclusivity. BioNTech is using AI-powered research to bring innovative therapies to patients more quickly. Gerresheimer is producing advanced packaging solutions for pharmaceuticals that have the potential to improve healthcare significantly. We take a look at current annual reports and value chains.
Read
Commented by Armin Schulz on October 2nd, 2024 | 07:00 CEST
Evotec, Nyxoah, Carl Zeiss Meditec – Biotech and medtech stocks with potential
The biotechnology and medical technology industries are driving medical innovation and offering exciting investment opportunities. Evotec, Nyxoah, and Carl Zeiss Meditec stand out among the companies that are particularly prominent in these areas. Evotec has established itself through its collaborative strategy in drug discovery and is using modern technologies such as AI to accelerate the discovery process. The emerging medtech company Nyxoah is focusing on innovative solutions for the treatment of sleep apnea. Carl Zeiss Meditec is a leader in ophthalmology and microsurgery with world-class optical devices and advanced visualization technologies. All three companies have recently seen their stock prices come under pressure and now offer an entry opportunity.
Read
Commented by André Will-Laudien on September 27th, 2024 | 07:00 CEST
150% turnaround likely! TUI, Saturn Oil + Gas, Plug Power, Novo Nordisk, and Evotec in focus
With the FED's latest interest rate cut, the way is paved for higher prices. In addition to the main performers, investors are increasingly turning their attention to equities that have so far seen little appreciation. The key question here is when the fundamentals will ultimately improve. This could then ensure that the analysts' bias finally turns and positive assessments are possible again. TUI, Evotec, and Plug Power are currently at very interesting points, while Saturn Oil & Gas is delivering results consistently and is now being recognized by institutional investors. Where are the opportunities for investors?
Read
Commented by André Will-Laudien on September 25th, 2024 | 07:00 CEST
The biotech rally of the century is on the horizon! 150% returns with BioNTech, Pfizer, Nyxoah, Bayer, or Evotec?
The stock market keeps climbing, and now it is moving even faster with a double-whammy interest rate cut from the Fed! In a surprising move, the US Federal Reserve pulls a 0.5% rate cut from its magic hat, boosting market sentiment. Now, it is certain that life will continue in the biotech sector. However, selecting the right stocks remains challenging. With a medium-term focus, paying attention to management quality is important because the recent price declines were too high in some cases. However, some research approaches promise a better future. BioNTech, Pfizer, and Bayer have already bottomed out. Nyxoah and Evotec are now showing the first signs of breaking out after a period of consolidation. What is the short-term outlook?
Read
Commented by André Will-Laudien on September 18th, 2024 | 07:30 CEST
Turnaround stocks – Here we go! 250% returns with thyssenkrupp, nucera, Evotec, VCI Global and A2Z Cust2Mate
The stock markets are going up and up, even in the most challenging stock market month of the year. Because the market had already corrected in July, the bulls say that the need to catch up is all the greater due to upcoming interest rate cuts by central banks. The bears believe that the valuation of tech and AI stocks, in particular, is already far too advanced and are hoping for a correction. Yet, green signals dominate daily, and now the question is which lagging stocks to invest in. Of course, it does not work without fundamentals, but sometimes insider buying is enough to lift sentiment. We select promising risk-return profiles for risk-conscious investors.
Read
Commented by Stefan Feulner on September 18th, 2024 | 07:00 CEST
CureVac, Nyxoah, and BioNTech with powerful upward momentum
Last week was another busy week on the world's stock markets. After the brief, painful corrections in August, the DAX and Dow Jones are preparing to return to their old highs. The precious metal gold has already reached these highs with flying colors thanks to the interest rate cut fantasy. The capital-intensive biotechnology sector is also benefiting from the possible interest rate cut, with several companies posting double-digit gains.
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by Fabian Lorenz on September 16th, 2024 | 07:00 CEST
Big news at BioNTech! Soon also at Nyxoah? What about Sartorius?
The more than 10% jump in BioNTech's share price at the beginning of the week surprised many investors. Was this the starting signal for a sustained upward trend? The biotech company will publish important data in the coming days. Nyxoah is also getting ready for the big bang. The medical technology company is on the verge of entering the US market with its high-tech product. The Belgian company is fully financed to tap into the world's largest healthcare market. Are Nyxoah shares about to take off? The Sartorius share has started a countermovement in recent days. Is there more to come for the share price?
Read